Erasca, Inc. Faces Securities Class Action After Patent Dispute and Patient Death
Erasca, Inc. is facing a securities class action following a significant stock drop triggered by patent infringement claims and news of a patient death.
San Francisco – Erasca, Inc. (NASDAQ: ERAS) is facing a securities class action lawsuit after its stock price plummeted by 48%, or $9.25 per share. The decline followed reports that competitor Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca's pan-RAS molecular glue, ERAS-0015. Additionally, news emerged that a patient died one month after receiving ERAS-0015.
The lawsuit aims to represent investors who purchased or acquired Erasca common stock between January 14, 2025, and April 26, 2026, and suffered substantial losses. The combined news wiped out over $2.8 billion in Erasca's market capitalization.
According to the complaint, Erasca had allegedly misled investors by comparing ERAS-0015's efficacy to RevMed's competing therapy and assuring them of its intellectual property protection. The truth reportedly surfaced on April 27, 2026, when Erasca disclosed it had received a letter from RevMed's legal counsel challenging its patent claims. The company also revealed the patient death that occurred after treatment.
National shareholder rights law firm Hagens Berman is investigating the matter. The firm alleges that Erasca may have intentionally misled investors regarding ERAS-0015's safety profile and its competitive standing. Investors who experienced significant losses are encouraged to contact the firm to discuss their legal options.